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Summary
Hypoxia unleashes the invasive and metastatic potential of tumor cells by largely unknown mechanisms. The Met tyrosine
kinase, a high affinity receptor for hepatocyte growth factor (HGF), plays a crucial role in controlling invasive growth and
is often overexpressed in cancer. Here we show that: (1) hypoxia activates transcription of the met protooncogene, resulting
in higher levels of Met; (2) hypoxic areas of tumors overexpress Met; (3) hypoxia amplifies HGF signaling; (4) hypoxia
synergizes with HGF in inducing invasion; (5) the proinvasive effects of hypoxia are mimicked by Met overexpression; and
(6) inhibition of Met expression prevents hypoxia-induced invasive growth. These data show that hypoxia promotes tumor
invasion by sensitizing cells to HGF stimulation, providing a molecular basis to explain Met overexpression in cancer.
Introduction Hill, 1990; Cairns et al., 2001; Postovit et al., 2002; Rofstad et
al., 2002).
In order to become metastatic, a neoplastic cell has to dis-Most tumors have acquired the ability to develop their own blood
vessels as they grow. However, the structure and architecture of rupt interactions with surrounding cells, cross the basal mem-
brane or parenchima of origin, to migrate through the extracellu-the tumor vasculature is highly disorganized compared to nor-
mal tissues, resulting in irregular and inefficient oxygen delivery. lar matrix, penetrate a blood or lymph vessel, and subsequently
extravasate into a foreign tissue, where it still has to implant,As a consequence, neoplastic lesions are riddled with regions
subjected to acute and chronic hypoxia (Harris, 2002; Ho¨ckel proliferate, and generate its own net of capillaries (Woodhouse
et al., 1997; Liotta and Kohn, 2001; Hanahan and Weinberg,and Vaupel, 2001; Vaupel et al., 1989). Although a limiting factor
for tumor growth, hypoxia appears to represent a positive stimu- 2000; Chambers et al., 2002). In addition, a cancer cell that
undertakes the metastatic route must acquire the ability to es-lus for invasion. In fact, clinical studies have clearly demon-
strated that the low pO2 tension within a neoplastic lesion is an cape death by “anoikis” (the absence of the home environment),
which triggers apoptosis of normal cells when they abandonindependent prognostic indicator of poor outcome and corre-
lates with an increased risk to develop distant metastases, their histological niche (Frisch and Francis, 1994; Frisch and
Screaton, 2001).independent of therapeutic treatment (Ho¨ckel et al., 1996, 1999;
Brizel et al., 1996, 1997; Sundfor et al., 1998). As a consequence of this complexity, the metastatic process
involves a variety of effector molecules that control cell prolifera-The higher malignancy of hypoxic tumors has been attrib-
uted to the ability of hypoxia to select for cells that are more tion, survival, motility, cell-cell contacts, and interactions with
the extracellular matrix, and is mastered by specific cytokinesresistant to apoptosis (Graeber et al., 1996; Yu et al., 2002) and
to induce the secretion of angiogenic factors (Shweiki et al., that orchestrate the coordinated completion of the program
(Liotta and Kohn, 2001). Perhaps the most well characterized1992; Forsythe et al., 1996; Harris, 2002). However, the forma-
tion of metastases is a biological phenomenon too complex to molecules among these coordinating cytokines are scatter fac-
tors (for a review see Trusolino and Comoglio, 2002).be explained solely on the basis of increased angiogenesis,
and experimental evidence suggests that hypoxia can directly The prototype of the scatter factor family is hepatocyte
growth factor (HGF), also known as scatter factor-1 (Nakamuraincrease tumor cell invasiveness (Young et al., 1988; Young and
S I G N I F I C A N C E
Much emphasis has been placed in recent years on hypoxia-induced neoangiogenesis, a biological process characterized by
migration of endothelial cells toward the tumor mass in order to restore a regular supply of oxygen. The data presented in this study
unveil a second, parallel mechanism that employs a symmetric and complementary strategy: it allows single neoplastic cells to
escape hypoxia by invading surrounding tissues where oxygen and nutrients are not limited. This phenomenon has important
implications in tumor biology. First, it provides evidence for an angiogenesis-independent, hypoxia-induced “invasive switch” that
links tumor hypoxia to increased malignancy. Second, it points to the therapeutic necessity of suppressing cell motility when targeting
tumor angiogenesis, in order to prevent the potential spread of cancer cells consequent to intratumoral oxygen deprivation.
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et al., 1986, 1989; Stoker et al., 1987; Gherardi et al., 1989; for As Figure 1A shows, hypoxia and CoCl2 treatment markedly
increased the levels of Met in all cells analyzed (only the dataa review see Rubin et al., 1993). HGF is a pleiotropic cytokine
relative to two cell lines are shown). To quantify the extentthat plays a major role in organ formation during embryogenesis
of this induction, we performed Western blot analysis of cells(Schmidt et al., 1995; Uehara et al., 1995; Woolf et al., 1995;
subjected to the same conditions and then measured Met signalTakayama et al., 1996; Andermarcher et al., 1996) and in tissue
intensity by chemiluminescence. Anti-actin antibodies werehomeostasis in the adult (Miyazawa et al., 1994; Yanagita et
used as controls for protein loading. The results of this analysisal., 1993; Yang et al., 1995; Matsumoto and Nakamura, 1997).
are summarized in Table 1. Representative experiments for fourInappropriate activation of the HGF pathway, as often observed
cell lines are shown in Figure 1B. To determine the kineticsin cancer, leads to a malignant process—known as invasive
of Met induction by hypoxia, we also performed time-coursegrowth—by which tumor cells weaken tissue constraints, mi-
experiments in two selected cell lines (A549 and U2-OS; Figuregrate, and invade foreign districts, where they give rise to meta-
1C). These experiments revealed that induction of Met beginsstases (Birchmeier et al., 1997; Vande Woude et al., 1997; Com-
to appear after approximately 12 hr of continuous exposure tooglio and Trusolino, 2002). Interestingly, the high-affinity HGF
a 3% oxygen environment.receptor, encoded by the met protooncogene, is activated in
human cancer either by point mutation (Schmidt et al., 1999;
Hypoxia increases the levels of met mRNAPark et al., 1999; Di Renzo et al., 2000) or—in the large majority
The effect of hypoxia on the expression of met mRNA wasof cases—by overexpression (Di Renzo et al., 1992, 1995; Liu
analyzed in the same panel of cells described above by Northernet al., 1992; Boix et al., 1994). Since met gene amplification is
blotting and quantified by radioimaging. As Table 1 shows, hyp-a rare event, the mechanisms underlying Met protein overex-
oxia or CoCl2 induced the levels of met mRNA in all cells testedpression in tumors remain obscure.
to an extent consistent with the data obtained by Western blotHere we show that hypoxia induces the expression of the
analysis. Figure 2A shows representative experiments for twoMet receptor both in vitro and in vivo. In cultured cells, the Met
cell lines. In time-course experiments (Figure 2B), met mRNAprotein and mRNA levels increase substantially after exposure
induction preceded by a few hours the increase in Met protein,to low oxygen tension. In experimental tumors, Met protein
and followed an induction pattern similar to that observed forlevels are highly upregulated in coincidence with hypoxic areas,
the HIF-1-inducible gene vegf. However, a major distinctionforming an expression gradient that is inversely proportional to
between vegf and met can be made based on their basal expres-blood vessel proximity. By analyzing the human met promoter,
sion. In fact, while both vegf and met expression are induced
we demonstrate that this induction is transcriptional and is medi-
by hypoxia, only met mRNA is detectable in normoxic condi-
ated by two Hypoxia Inducible Factor-1 binding sites (Semenza,
tions. This difference in regulation conceivably reflects different
2001) and an AP-1 site. We also show that hypoxia-induced physiological functions: while VEGF may be dispensable in nor-
Met overexpression results in increased sensitivity to HGF, and moxic conditions, Met plays an important role in controlling cell
that low oxygen tension and HGF synergize in inducing cell proliferation, motility, and survival.
motility and invasion. Finally, using a gene transfer approach
and RNA interference technology, we provide evidence that Hypoxia activates the met promoter
expression of Met at the levels achieved by hypoxia is necessary The promoter region of the human met gene contains several
and sufficient to sensitize cells to minimal amounts of HGF and putative HIF-1 binding sites (HBSs)—both in sense and anti-
thus to activate the invasive growth program. sense orientation—through which HIF-1 promotes gene tran-
All together, these data suggest that the HGF receptor is scription in hypoxic conditions (Semenza, 2001; Figure 3A). To
an important mediator of hypoxia-induced tumor invasiveness, study the effect of hypoxia on met transcription, we subcloned
providing a molecular explanation for Met overexpression in progressively shorter fragments of the human met promoter
cancer. (Gambarotta et al., 1994) into a reporter plasmid upstream to
a luciferase gene, thus generating four different promoter con-
Results structs (P1, from 2619 to 353; P2, from 295 to 353; P3,
from32 to353; P4, from89 to353). We then transfected
Hypoxia induces the expression of the Met protein the various reporter plasmids into suitable cell lines and incu-
To investigate a possible role of Met in the cellular response to bated cells in normoxic or hypoxic conditions. In a separate set
hypoxia, we analyzed the expression of the Met protein in differ- of experiments, we cotransfected the same reporter plasmids
ent cells cultured in normoxic or hypoxic conditions. To this with an expression vector containing either no insert or a hif-1
end, cell lines established from normal tissues (B5/589, human cDNA, and then incubated cells in normoxic conditions. An
breast epithelium; MLP-29, murine hepatocyte precursors) or inactive, mutant form of HIF-1 (Richard et al., 2000) was used
tumors (A549, human lung carcinoma; SK-OV-3, human ovarian as a negative control. Luciferase activity of transfected cells
carcinoma; SiHa, human cervical carcinoma; HepG2, human was analyzed to determine promoter activity. As shown in Figure
hepatocarcinoma; U2-OS, human osteosarcoma) were serum- 3B, hypoxia or exogenous wild-type HIF-1 increased transcrip-
starved to minimize the effect of growth factors on Met expres- tion from the met promoter by 2–3 fold, while they had no effect
sion and then incubated in the presence of 21% O2, 3% O2, or on a control reporter plasmid (Basic). Although this extent of
21% O2 plus CoCl2, a compound that mimics the effects of induction might seem modest, it should be stressed that the
hypoxia by inducing Hypoxia Inducible Factor-1 stabilization promoters of other genes known to be induced by hypoxia
(HIF-1; Yuan et al., 2003). After 48 hr, cells were analyzed display comparable changes in activity when tested in similar
by immunofluorescence microscopy using anti-Met antibodies. assays (Yamashita et al., 2001; Xu et al., 2000; Maity and Solo-
mon, 2000; Gerber et al., 1997; Levy et al., 1995; Kimura et al.,Anti-HIF-1 antibodies and phalloidin were used as controls.
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Figure 1. Hypoxia induces the Met protein
A: Immunofluorescence analysis by confocal mi-
croscopy. Cells (see text) were incubated in nor-
moxia (N), hypoxia (H), or stimulated with CoCl2
(Co) for 48 hr, and then stained with anti-HIF-1
antibodies (in blue) or anti-Met antibodies (in
red). Counterstaining with phalloidin is shown in
green. The bar represents a 50 m indicator.
B: Western blot analysis. Cells were treated as
in A and total protein extracts were analyzed
for Met protein expression using anti-Met anti-
bodies. Anti-actin antibodies were used as con-
trol of protein loading. Control, untreated cells
at time zero.
C: Time-course analysis of Met expression. Cells
were incubated in hypoxic conditions for the in-
dicated times and Met expression was deter-
mined by Western blot analysis as in B.
2000). By this analysis, the minimal hypoxia-responsive region also reduced the ability to respond to hypoxia or HIF-1, but
severely impaired the basal activity of the promoter as well.of the met promoter could be restricted to a 264 bp fragment
comprised between a SmaI restriction site (located 89 bp down- Mutagenesis of the same sites in the context of a P2 promoter
construct also impaired its transcriptional response to hypoxia,stream the transcriptional start site) and an AvaI restriction site
situated in the first untranslated exon (at position 353). This while mutagenesis of HBS-2, HBS-3, asHBS-1, or asHBS-2 had
no effect (data not shown). Taken together, these data showregion (P4) contains an AP-1 site (which has been assigned a
central role in controlling met transcription; Seol et al., 2000) that hypoxia induces transcription from the met promoter and
that this transcriptional activation is mediated by two differentand two putative HIF-1 binding sites (HBS-4 and -5). We muta-
genized these sites individually and compared the activity of HBSs and an AP-1 site, all located in the 5 untranslated region
(5 UTR). This situation is not unique, since the location of aeach mutant P4 promoter to the activity of wild-type P4 pro-
moter. As shown in Figure 3C, mutagenesis of HBS-4 or HBS-5 functional HBS in the 5 UTR of a hypoxia-responsive gene has
already been reported (Sa´nchez-Elsner et al., 2002). Furthermore,resulted in a significantly reduced transcriptional response to
hypoxia or to exogenous HIF-1. Mutagenesis of the AP-1 site cooperation between HBSs and AP-1 sites in the transcriptional
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Table 1. Hypoxia and CoCl2 induce met mRNA and Met protein expression in normal and tumor cell lines
Cell line analyzed Fold induction by hypoxia Fold induction by CoCl2
Name Origin met mRNA Met protein met mRNA Met protein
B5/589 h. breast epithelium 2.3  0.3 2.0  0.2 2.5  0.7 2.2  0.1
A549 h. lung carcinoma 3.3  0.2 3.1  0.2 3.2  0.4 2.5  0.2
U2-OS h. osteosarcoma 3.5  0.6 3.2  0.9 3.0  0.2 2.5  0.2
SiHa h. cervical carcinoma 3.1  0.3 2.9  0.2 2.0  0.4 1.9  0.2
HepG2 h. hepatocarcinoma 2.5  0.2 2.6  0.1 2.3  0.6 2.1  0.2
SK-OV-3 h. ovarian carcinoma 2.6  0.3 2.5  0.2 2.8  0.2 2.3  0.2
MLP-29 m. hepatocyte precursors 2.7  0.4 3.0  0.7 3.4  0.3 4.2  0.4
The levels of met mRNA and Met protein were determined in the indicated human (h.) or mouse (m.) cell lines as follows: cells were grown to 80% confluence
in low serum, serum-starved for at least 24 hours, and then incubated in a 21% O2 environment, in a 3% O2 environment, or in a 21% O2 environment in the
presence of 100 M CoCl2 for an additional 48 hours. The levels of met mRNA were determined by Northern blotting of total RNA using a full-length met
cDNA radiolabeled probe, quantified using a phosphoimager apparatus with dedicated software, and normalized to loading controls. The levels of Met
proteins were determined by Western blotting of total protein extracts using anti-Met antibodies, quantified directly by short-wave chemiluminescence
using a dedicated optical scanner and software, and normalized to loading controls. Values (mean  SD) refer to at least three independent experimental
determinations.
response to hypoxia has also been observed for other genes
(Yamashita et al., 2001; Damert et al., 1997; Kimura et al., 2000;
Norris and Millhorn, 1995; for a review see Michiels et al., 2001).
Met is upregulated in hypoxic regions of tumors
Hypoxia is a common feature of solid tumors, even in highly
vascularized lesions. This is due to the disorganized architecture
of tumor vessels, which does not guarantee a homogeneous
oxygen supply to the tumor mass. As a result, most tumors
contain several regions with lower O2 tension, which can be
visualized by staining tumor sections with anti-HIF-1 antibod-
ies (Vukovic et al., 2001). To test whether Met is upregulated
by hypoxia in vivo, we analyzed Met expression in hypoxic
regions of experimental tumors induced in nude mice by subcu-
taneous injection of human cancer xenografts and in bona fide
human tumor samples (Figure 4). In a first approach, tumor
sections were double-stained with anti-HIF-1 antibodies and
anti-human Met antibodies, and sections were analyzed by con-
focal microscopy. As expected, HIF-1 signal was only barely
detectable in the vast majority of tumor cells, but several “hot
spots” of intense HIF-1 staining could be identified throughout
the section, both in experimental tumors and in human samples.
On the contrary, Met was detectable in all tumor cells, but
its levels dramatically increased in coincidence with HIF-1-
positive, hypoxic areas. Figure 4A shows representative micro-
scopic fields in which colocalization of HIF-1 (in red) and Met
(in green) is observed (column 1, cervical carcinoma xenograft;
column 3, human breast carcinoma). Antibody specificity was
determined using epitope-competed anti-Met antibodies (col-
umns 2 and 4). In a second approach, we costained tumor
sections with anti-Met antibodies and antibodies against the
endothelial marker CD-31. Confocal microscopy analysis re-
Figure 2. Hypoxia induces met mRNA
vealed that—consistent with a role of oxygen tension in regulat-
A: Northern blot analysis. Cells were subjected to normoxia (21% O2), hypoxia ing Met expression—cells expressing higher levels of Met are(3% O2), or CoCl2 treatment for 48 hr, and the levels of met mRNA were
localized in regions distant from blood vessels, whereas cellsdetermined by Northern blot analysis. Control, untreated cells at time zero.
B: Time course analysis of met mRNA expression. Cells were incubated close to capillaries express very low levels of Met. This is ex-
in hypoxic conditions for the indicated times and met mRNA levels were emplified in Figure 4B (red, CD-31; green, Met) that shows
determined by Northern blot analysis. The induction of vegf mRNA is shown representative microscopic fields (column 1, cervical carcinomaas a positive control.
xenograft; column 3, human breast carcinoma). Also in this
analysis, anti-Met antibody specificity was demonstrated by
epitope competition (columns 2 and 4). We therefore conclude
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Figure 3. Hypoxia induces met transcription
A: Nucleotide sequence of the human met pro-
moter. Nucleotide 1 corresponds to the start
site according to Gambarotta et al., 1994. Puta-
tive HIF-1 binding sites in sense orientation (HBSs)
or in antisense orientation (asHBSs) are shown in
red (the core consensus sequence “CGTG” is
underlined). An AP-1 site is indicated in green.
Restriction sites used for subcloning (SmaI, AvaII)
are underlined in black.
B: Analysis of promoter (luciferase) activity using
U2-OS cells (overlapping results were obtained
with MLP-29 cells; not shown). Left histogram:
cells were transfected with the various promoter
constructs (P1-4) and then incubated in nor-
moxic (21% O2) or hypoxic (3% O2) conditions.
Right histogram: cells were cotransfected with
P1-4 and an expression vector containing either
no insert or a hif-1 cDNA, and then incubated
in normoxic conditions. Luciferase activity was
normalized for transfection efficiency using a Re-
nilla reporter plasmid. WT HIF-1, wild-type HIF-1;
Mut. HIF-1, inactive HIF-1 mutant; Basic, pro-
moterless reporter construct; a.u., arbitrary units.
C: Site-directed mutagenesis analysis. Cells were
transfected as in B and the activity of wild-
type (WT) P4 construct was compared with the
activity of mutagenized P4 constructs in which
putative trascriptional elements (HBS-4, HBS-5,
AP-1) had been destroyed by site-directed mu-
tagenesis.
that Met is sensitive to oxygen gradients in vivo, and that hypoxic whether these changes in protein levels are significant from a
regions of solid tumors overexpress Met. biological viewpoint, we analyzed whether a hypoxic environ-
ment could affect HGF-induced Met activation and signaling.
To this end, the same panel of cells used above was deprivedHypoxia sensitizes cells to HGF stimulation
of serum growth factor to minimize background, and then incu-The data presented above provide evidence that the Met recep-
tor is induced by hypoxia both in vitro and in vivo. To assess bated in normoxic or hypoxic conditions for 48 hr. Immediately
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Figure 4. Met expression in tumors correlates directly with hypoxia and inversely with proximity to blood vessels
Tumor sections derived from an experimental cervical carcinoma xenograft (columns 1 and 2) or from a bona fide human breast carcinoma (columns 3
and 4) were analyzed by confocal microscopy.
A: Sections were double stained with antibodies against the hypoxic marker HIF-1 (in red) and against the Met receptor (in green). Control of anti-Met
antibody specificity was performed by epitope competition (Comp. MET; columns 2 and 4).
B: Sections derived from the same tumors were costained with antibodies against the endothelial marker CD-31 (in red) and against the Met receptor (in
green). Anti-Met antibody specificity was determined as in A (columns 2 and 4). The yellow bar represents a 100 m indicator.
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Figure 5. Hypoxia amplifies HGF signaling
A: Met receptor activation analysis in cells prein-
cubated in normoxia or hypoxia. Following stimu-
lation with HGF or no factor, cellular proteins
were immunoprecipitated using anti-Met anti-
bodies and analyzed by Western blotting using
anti-phosphotyrosine antibodies. Signal intensity
was quantified as described in Experimental Pro-
cedures. The histogram shows absolute Met tyro-
sine phosphorylation levels (Met pTyr; a.u., arbi-
trary units). Values are the mean of three
independent experiments.
B: Met signal transduction analysis. Cells incu-
bated in normoxia (N) or hypoxia (H) were stimu-
lated as described in A and then lysed. Protein
extracts were immunoprecipitated using anti-
Gab-1 antibodies and analyzed by Western blot-
ting using anti-phosphotyrosine antibodies. The
same blots were reprobed using anti-Gab-1 anti-
bodies to normalize for the amount of Gab-1.
after, cells were stimulated with HGF or no factor as control for affect cell motility in classic model systems used to test HGF
10 min, and then lysed. Cellular proteins were immunoprecipi- activity. The most classic and simple of these is the “scatter”
tated using anti-Met antibodies and analyzed by Western blot assay (Stoker and Gherardi, 1991), in which cells are induced
using anti-phosphotyrosine antibodies. Strikingly, while hypoxia by HGF (also known as scatter factor) to loosen cell-cell interac-
had little effect on Met basal tyrosine phosphorylation, it dramat- tions, to degrade extracellular matrix, and to scatter within a
ically amplified the response to HGF in all cells analyzed (Figure few hours. We assayed the effect of hypoxia on HGF-induced
5A). As a second read-out for Met activity, we also analyzed the cell scattering on MLP-29, HepG2, and U2-OS cells. As for
activation of one of its key signal transducers, the multiadaptor all experiments described so far, cells were serum-starved to
protein Gab-1 (Weidner et al., 1996). In experiments analogous reduce any background due to growth factors (including minimal
to those described above, cellular proteins were immunoprecipi- amounts of HGF contained in fetal serum), preincubated in nor-
tated using anti-Gab-1 antibodies and then analyzed by Western moxia or hypoxia for 24 hr, and then stimulated with HGF or no
blot using anti-phosphotyrosine antibodies. The same blots factor. After 24 hr, cells were fixed, stained with fluorescinated
were subsequently reprobed with anti-Gab-1 antibodies to as- phalloidin, and analyzed by fluorescence microscopy. As shown
sess Gab-1 levels and with anti-Met antibodies to determine the in Figure 6A, HGF induced the typical changes in morphology
association between Gab-1 and the Met receptor. Remarkably, (acquisition of a “fibroblast-like” shape, sprouting of pseudo-
hypoxia amplified several fold (3–9 fold depending on cell line) podia) and a motile response (scattering) in all cell lines ana-
the extent of Gab-1 phosphorylation in response to HGF (Figure lyzed. Consistent with our data on Met activation, hypoxia per
5B), and dramatically increased the amount of Met associated se did not significantly affect basal cell morphology, but strongly
with Gab-1 (not shown). Again, the basal levels of Gab-1 phos-
synergized with HGF in inducing cell scattering. In end-point
phorylation and association with Met were not significantly
titration assays performed with progressive 1:2 ligand dilutions,changed by hypoxia itself. The slight changes in Gab-1 levels
hypoxia amplified HGF-induced cell scattering by at least 2observed in these experiments are probably due to altered im-
dilutions (not shown). We next analyzed the effect of hypoxiamunoprecipitation efficiency (consequent to changes in epitope
on HGF-induced cell migration by a Matrigel invasion assaypresentation or protein sequestration by other signal transduc-
(Medico et al., 1996). This assay measures the ability of cellsers). In fact, direct Western blot analysis of the same protein
to migrate through a reconstituted extracellular matrix in re-extracts did not reveal any significant change in Gab-1 levels
sponse to HGF. Cells (SiHa and U2-OS) were plated onto a(not shown). We conclude that hypoxia sensitizes cells to HGF
layer of Matrigel, serum-starved to minimize any interferencestimulation and amplifies HGF signaling.
by serum growth factors, and then incubated in normoxic or
hypoxic conditions, either in the absence or presence of HGF.Hypoxia enhances HGF-induced cell motility
Again in accordance with our biochemical data, hypoxia did notSince Met mediates motile cues in both physiologic and patho-
logic conditions, we set out to investigate whether hypoxia could stimulate basal cell migration, but significantly amplified the
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Figure 6. Hypoxia and HGF synergize in inducing cell motility and invasion
A: Scatter assay. Serum-starved cells were preincubated in normoxia (21% O2) or hypoxia (3% O2) for 24 hr and then stimulated with HGF or no factor in
the same conditions for additional 24 hr. Following staining with fluoresceinated phalloidin, cells were analyzed by confocal microscopy.
B: Matrigel invasion assay. Cells seeded onto a layer of Matrigel were serum-starved and incubated in normoxia or hypoxia. After 24 hr, cells were stimulated
with HGF in the same conditions for additional 24 hr. The number of cells migrated through the Matrigel layer was scored by microscopy following staining
with crystal violet.
C: Collagen invasion assay. The ability of MLP-29 and U2-OS cells to form branched tubular structures in a three-dimensional collagen matrix was tested in
normoxia (N) and hypoxia (H), with or without exogenous HGF. These experiments were run in the presence of 10% FBS.
A R T I C L E
Figure 7. Met upregulation mediates hypoxia-
induced branching morphogenesis
A: Overexpression of exogenous Met is sufficient
to induce branching morphogenesis in normoxic
conditions. Western blot: Met expression in wild-
type U2-OS cells in normoxia (21% O2) or hypoxia
(3% O2) is compared to Met expression in U2-OS
cells transfected with the indicated plasmid con-
structs in normoxic conditions. WB, Western blot.
Histogram: stable transfectants analyzed by
Western blot were subjected to a branching
morphogenesis assay in normoxic conditions (N;
all groups) or in hypoxic conditions (H; empty
vector only). The percentage of branched colo-
nies (sprouted spheroids) was scored by micros-
copy. Values (mean  sd) refer to three experi-
ments performed in quadruplicate. Empty V,
empty vector; WT Met, wild-type Met; -Met,
-chain Met; K1128A Met, kinase-inactive Met.
B: Inhibition of Met expression by RNA interfer-
ence prevents hypoxia-induced branching mor-
phogenesis. Western blot: Met knock-down.
U2-OS cells were transfected with no oligo, dou-
ble strand met oligoribonucleotides (MET1 
MET3) or mutant double strand met oligori-
bonucleotides (MET1*  MET3*), incubated in
normoxic or hypoxic conditions, and then ana-
lyzed by Western blotting as indicated. Histo-
gram: transfectants analyzed by Western blot
were subjected to a branching morphogenesis
assay in normoxic (N) or hypoxic (H) conditions,
either in the presence or absence of HGF.
Branched colonies were scored as in A. Values
(mean  sd) refer to three experiments per-
formed in triplicate.
response to HGF in all cells tested (Figure 6B). A similar effect matically amplified the proinvasive effect of HGF (only the data
relative to U2-OS and MLP-29 cells are shown). Stimulationwas also achieved by stimulation with CoCl2 (data not shown).
with CoCl2 also achieved a strong synergistic effect with HGF
(data not shown). However, in contrast with the results obtainedHypoxia and HGF synergize in inducing invasion
in the other bioassays performed, low pO2 also inducedHGF is a proinvasive cytokine par excellence. The genetic pro-
branching morphogenesis on its own, as previously observedgram activated by HGF leads epithelial cells to abandon their
in renal cells (Maranchie et al., 2002). Since the cell lines usedsite of origin within a tissue, to migrate through the extracellular
in our experiments proved to be negative for HGF expressionmatrix, and to invade adjacent tissues (Brinkmann et al., 1995;
by RT-PCR analysis in both normoxic and hypoxic conditionsBirchmeier et al., 1997). The most reliable in vitro assay that
(data not shown), the latter phenomenon can be explained eitherdependably measures HGF-induced invasiveness is the colla-
by implying a mechanism totally unrelated to Met, or by hypothe-gen invasion assay (Montesano et al., 1991). This assay—also
sizing that hypoxia-induced Met overexpression sensitizes cellsknown as the “branching morphogenesis” assay—highlights the
to the minimal amounts of HGF contained in serum. This waspotential of cells to invade a tridimensional collagen gel, forming
tested directly by the following experiments.typical branched structures. This invasion process represents
the summa of the invasive growth phenotype and results from
the fine integration of all the pleiotropic effects induced by HGF, Met overexpression is sufficient to induce
branching morphogenesisincluding cell proliferation, motility, differentiation, and survival.
To study the effect of hypoxia on cell invasion, we performed The ability of renal epithelial cells to form branched structures
under hypoxic conditions in the absence of exogenous HGFa collagen invasion assay using different cell lines (U2-OS,
MLP-29, SiHa) in normoxic or hypoxic conditions. It should be has been proposed to depend upon increased levels of HIF-1,
as overexpression of exogenous HIF-1 in the same cells ledstressed that—in contrast to the other bioassays described
above—collagen invasion assays must be performed in high to a similar phenotype in normoxic conditions (Maranchie et al.,
2002). This suggests that a yet unidentified transcriptional targetserum in order to prevent massive cell death. Preformed cell
spheroids were embedded into a collagen gel, preincubated in of HIF-1 is involved in the invasive growth process. To investi-
gate on a possible direct cause-effect relationship between Met21% O2 or 3% O2 for 24 hr, and then stimulated with HGF or
no factor in the same oxygen environment. After 24 hr, cell induction by hypoxia and increased invasion, we overexpressed
exogenous Met at levels comparable to those achieved by en-colonies were analyzed by microscopy and representative
spheroids photographed. As shown in Figure 6C, hypoxia dra- dogenous Met under hypoxic conditions, and tested whether
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this was sufficient to induce branching morphogenesis in nor- tated met oligos had no effect. RNA interference also abolished
the response to exogenous HGF in both normoxic and hypoxicmoxic conditions. To this end, we employed an expression
vector with a weak promoter (Michieli et al., 1999). Stable U2-OS conditions, demonstrating that Met expression is efficiently in-
hibited from a biologic viewpoint. We thus conclude that Mettransfectants were obtained (see Figure 7A, Western blot panel)
that expressed exogenous wild-type Met (WT Met), a kinase- expression is necessary in order to observe the proinvasive
effect of hypoxia, at least in the branching morphogenesis assayinactive Met (K1128A Met), or an engineered Met—consisting
of the-chain only—deprived of the functional domain responsi- and in the cell systems analyzed. Taken together, the data pre-
sented here suggest that hypoxia sensitizes cells to HGF byble for interaction with HGF (-Met; Michieli et al., 1999). The
latter form of Met is properly exposed at the cell surface, but increasing Met levels, thus activating an invasive growth pro-
gram that leads to cell migration and extracellular matrix in-is not activated by HGF. However, -Met responds biologically
to ligand-mimetic antibodies directed against the extracellular vasion.
portion of the Met -chain and is indistinguishable from wild-
type Met in kinase assays, thus demonstrating that deletion of Discussion
the HGF-interacting domain does not alter the overall functional-
ity of the receptor (Michieli et al., 1999). Cells transfected with The data presented in this study demonstrate that Met is in-
duced under hypoxic conditions both in vitro and in vivo. Theyempty vector (Empty V) were used as control. Transfected cells
were subjected to a branching morphogenesis assay in nor- also show that Met upregulation by hypoxia results in increased
sensitivity to HGF stimulation, and that HGF and hypoxia syner-moxic conditions (all groups) or in hypoxic conditions (empty
vector only). The percentage of “sprouted” spheroids was calcu- gize in inducing invasive growth.
The Met receptor has been shown to be overexpressed inlated as described in Experimental Procedures. As shown in
Figure 7A (histogram), overexpression of exogenous wild-type a large number of human neoplastic lesions, but the molecular
mechanisms underlying this upregulation have not been clarifiedMet in normoxic conditions (WT Met N) closely reproduced the
proinvasive effect of hypoxia in control cells (Empty VH). This so far. Importantly—as stated above—higher levels of Met are
due to increased gene expression rather than gene amplificationeffect depends on Met kinase activity because the kinase-inac-
tive form of Met did not induce branching morphogenesis in the vast majority of cases. Since hypoxia is a common feature
of most solid tumors, our data provide a molecular explanation(K1128A Met N). Interestingly, impairment of the ability of Met
to interact with HGF completely abrogated the proinvasive effect for these observations and suggest that hypoxia is an important
factor determining the levels of Met in cancer. Interestingly, Metconsequent to receptor overexpression (-Met N). It can there-
fore be concluded (1) that Met overexpression is sufficient to has been shown to be overexpressed in renal cell carcinomas
bearing genetic alterations in the vhl tumor suppressor geneinduce branching morphogenesis in the presence of serum, and
(2) that interaction with HGF (contained in serum) is indispens- (Oh et al., 2002), and the VHL protein has been found to inhibit
HGF-induced renal cell invasion (Koochekpour et al., 1999; Mar-able to achieve this proinvasive effect. With regard to this, we
determined that HGF can be affinity-purified from fetal bovine anchie et al., 2002). Given the pivotal role of the VHL protein in
targeting HIF-1 to proteolytic degradation in normoxic condi-serum using the extracellular portion of human Met, and that
hypoxia dramatically amplifies the ability of serum to phosphory- tions (Maxwell et al., 1999), our finding that HIF-1 contributes to
met gene expression provides a detailed molecular mechanismlate Met in receptor activation experiments similar to those de-
scribed in Figure 5 (data not shown). underlying the above biological observations.
Our Met activation analysis revealed that a 3-fold increase
in protein levels—which might appear a modest change in bio-Inhibition of Met expression prevents hypoxia-induced
invasive growth chemical terms—results in a dramatic amplification of signal
transduction downstream of Met. This can be explained by theTo further strengthen the idea that Met induction by hypoxia is
responsible for the observed invasive phenotype, we knocked following considerations. Firstly, activation of the Met kinase is
autocatalytic and intermolecular (Naldini et al., 1991). Upon liganddown Met expression in U2-OS cells or MLP-29 cells by RNA
interference (Hannon, 2002). To this end, cells were transfected stimulation, receptor oligomerization occurs, and trans-phos-
phorylation between sister protomers results in kinase activa-with two 19-base pairs, double-stranded oligoribonucleotides
derived from two distinct regions of met cDNA in which the tion. Activated receptors in turn phosphorylate other protomers,
thus promoting an enzymatic chain reaction. Intuitively, such anucleotide sequence is completely identical in the mouse and
human species. Cells transfected with point-mutated met oligos process—an autocatalytic enzymatic reaction—is characterized
by a nonlinear relation between receptor concentration and re-or no oligo were used as controls. As revealed by Western
blot analysis using anti-Met antibodies (Figure 7B, Western blot action velocity. Secondly, the Met receptor has recently been
shown to interact with other receptor species that amplify itspanel), transfection of wild-type met oligos (MET1-MET3) effi-
ciently reduced Met expression in both normoxia and hypoxia, signal (Orian-Rousseau et al., 2002; Trusolino et al., 2001), en-
hance its clustering (Giordano et al., 2002), or trans-phosphory-while mutated met oligos (MET1*-MET3*) had no effect (only
the data relative to U2-OS are shown). Anti-actin antibodies late the receptor (Follenzi et al., 2000). Thanks to these physio-
logical amplification systems, a modest increase in Met levelswere used as control of protein loading. Transfected cells were
subjected to a branching morphogenesis assay in normoxic may elicit more important downstream effects following HGF
stimulation. In the long term—as observed for instance in hyp-or hypoxic conditions, either in the presence or absence of
exogenous HGF. The percentage of sprouted spheroids was oxic areas of tumors—a positive feedback loop may contribute
to sustain and amplify Met overexpression, since the Met path-quantified as above. As shown in Figure 7B (histogram), inhibi-
tion of Met expression by RNA interference completely pre- way induces both the met gene itself (Boccaccio et al., 1994)
and HIF-1 activity (Tacchini et al., 2001).vented hypoxia-induced branching morphogenesis, while mu-
356 CANCER CELL : APRIL 2003
A R T I C L E
The observation that hypoxia sensitizes cells to HGF stimu- On the other hand, our data suggest that effective tumor
lation has important potential implications in cancer biology. In treatment could be achieved by combining antiangiogenic ther-
fact, HGF is ubiquitously present at high concentrations in apy with antiinvasive drugs, such as Met inhibitors (Boccaccio
plasma and in the extracellular matrix of tissues, where it accu- et al., 1998; Bardelli et al., 1999; Morotti et al., 2002) or HGF
mulates—due to its affinity for proteoglycans (Lyon et al., antagonists (Date et al., 1998; Michieli et al., 1999). This would
1994) —under the form of inactive precursor (pro-HGF). Pro- perhaps achieve efficient tumor “suffocation” while preventing
HGF is converted into active HGF in tissues by urokinase (uPA), the escape of cancer cells from hypoxic areas.
a protease of the plasminogen cascade (Naldini et al., 1992).
Experimental proceduresSince virtually all tumors—and invasive ones in particular—
overexpress urokinase (Aguirre Ghiso et al., 1999), it is reasonable
Cell cultureto predict that active HGF is not limiting in neoplastic lesions.
The following cell lines were purchased from ATCC (Rockville, MD): HepG2,
Therefore, hypoxia-induced sensitization to HGF may impor-
SiHa, A549, SK-OV-3, and U2-OS. MLP-29 cells were obtained as described
tantly contribute to increase the invasive behavior of a tumor. (Medico et al., 1996). B5/589 cells were a gift of Dr. Jacalyn H. Pierce (NCI
Given the pivotal role that the Met receptor plays in tumor Bethesda, MD). Cells were maintained in DMEM (HepG2, SiHa, SK-OV-3),
invasion and metastasis, the results obtained in this work are Iscove’s DMEM (U2-OS), or RPMI (A549, B5/589), all supplemented with
10% FBS (Sigma, St. Louis, MO). B5/589 were grown in the presence of 10particularly relevant to explain why hypoxia increases the malig-
ng/ml human recombinant EGF (Sigma). A 3% O2 environment was obtainednancy of neoplastic lesions. Until now, great emphasis has been
using a Heraeus BB 6220 oxygen electrode incubator (Heraeus, Hanau,placed on hypoxia-induced neoangiogenesis, mediated chiefly
Germany). CoCl2 (Merck, Darmstadt, Germany) was used at a concentrationby secretion of VEGF. This molecular phenomenon has actually
of 100 M.
become a paradigm of the cellular response to hypoxia, and
has been assigned a major role in determining a malignant Biological assays
conversion (the angiogenic switch) of the cancer lesion. Indeed, For the scatter assay, MLP-29, U2-OS, and HepG2 cells were seeded (1 
the secretion of angiogenic factors can be interpreted as a 104 cells/well) on glass coverslips in 24-well plates in medium supplemented
with 2% FBS. After adhesion, cells were serum-starved and incubated inconcrete attempt of the tumor mass to restore a normal oxygen-
normoxic or hypoxic conditions for 24 hr. Cells were then stimulated with 15ation rate to cancer cells.
ng/ml HGF (R&D Systems, Minneapolis, MN) and incubated in the indicatedOur data provide evidence for a second type of cellular
conditions for an additional 24 hr. Cells were fixed, stained with fluorescein-reaction to oxygen deprivation—symmetric and complementary
ated phalloidin (Sigma), analyzed by confocal microscopy, and photo-
to the angiogenic response from a strategic viewpoint—that graphed. Invasion assays were performed in Transwell chambers (Corning
leads to an invasive switch of the tumor mass. In fact, the results Costar, Cambridge, MA). The upper side of the filters was coated with
presented here show that cells subjected to hypoxia activate Matrigel (Collaborative Research, Waltham, MA) at a concentration of 115
g/cm2 . Cells were seeded (1  105 cells/well) onto the layer of Matrigela motility program and start invading the extracellular matrix,
using 2% FBS-containing medium, serum-starved after 5 hr, preincubatedresembling the typical features of the invasive growth pheno-
for 24 hr in normoxia or hypoxia, and then stimulated with 30 ng/ml oftype. Our gene transfer experiments and RNA interference anal-
recombinant HGF for 24 hr. At the end of the treatment, cells on the upperysis also prove that this increased invasiveness is due to higher
side of the filters were mechanically removed, and those migrated onto the
levels of Met. It could thus be suggested that increased motility lower side were fixed with 11% glutaraldehyde, stained with crystal violet,
and invasion represent the manifestation of a cellular plan aimed and counted. Collagen invasion assays were performed using preformed
at escaping the hostile hypoxic environment, attempting to colo- spheroids as described (Meyer et al., 1999). Briefly, spheroids were gener-
ated by incubating cells overnight (700 cells/well) in nonadherent 96-wellnize the adjacent tissue(s) where oxygen and nutrients are not
plates (Greiner, Frickenhausen, Germany) in the presence of 0.24 g/ml meth-limited. This mechanism could also play an important role during
ylcellulose (Sigma). Spheroids were embedded into a collagen matrix con-embryo development or tissue regeneration, where oxygen gra-
taining 1.3 mg/ml type I collagen from rat tail (BD Biosciences, Bedford,dients represent signals for morphogenetic invasive processes,
MA) and 10% FBS using 96-well plates (40 spheroids/well). Embeddedparticularly for the formation of branched, tubular organs.
spheroids were preincubated in normoxia or hypoxia for 24 hr, and then
The notion that hypoxia activates motile and invasive cues stimulated with 30 ng/ml HGF or no factor for 24 hr in the same oxygen
in tumor cells has important therapeutic implications. Following environment. The percentage of sprouted spheroids was scored by micros-
the initial observations that natural antiangiogenic polypeptides copy by analyzing all spheroids contained in each well.
could function as potent tumor suppressors in mice (O’Reilly
In vitro immunofluorescenceet al., 1994), several therapeutic strategies have been attempted
For analysis of Met expression, cells were plated on collagen-coated glassto contain tumor growth by suppressing neoangiogenesis. This
coverslips, serum-starved, and then incubated in the indicated conditionsapproach has achieved successful results in many experimental
(normoxia, hypoxia, or normoxia plus 100 M CoCl2). After 48 hr, cellssystems, and some antiangiogenic compounds are currently
were fixed (3% paraformaldehyde, 4% sucrose), permeabilized (0.2% Triton
being tested in clinical trials (Folkman, 1999). However, as our X-100), washed (0.2% BSA in PBS), and blocked (2% BSA). Human cells
knowledge on tumor angiogenesis increases, it has become (HepG2, SiHa, A549, SK-OV-3, U2-OS, B5/589) were incubated with a mix-
clear that this strategy has the important drawback of inducing ture of two anti-human Met monoclonal antibodies (DO-24 and DN-30; Prat
et al., 1998) or an anti-HIF-1 monoclonal antibody (a gift of Prof. Antoniotumor hypoxia (Blagosklonny, 2001). This issue has recently
Bargellesi, Istituto Nazionale per la Ricerca sul Cancro, Genova, Italy).been shown to be crucial for the therapeutic outcome, since it
MLP-29 cells were incubated with anti-mouse Met rabbit polyclonal antibod-allows for selection of more aggressive tumor cells (Yu et al.,
ies (SP260; Santa Cruz, Santa Cruz, CA). Incubation with the appropriate2002). Our results raise further concerns on the efficacy of anti-
Alexa Fluor 546-tagged secondary antibody (Molecular Probes, Eugene, OR)
angiogenic therapy per se, because they suggest that reduced was performed together with FITC-conjugated phalloidin (Sigma). Cells were
tumor vascularization—while inhibiting tumor growth—would then mounted in Mowiol 4-88 (Hoechst, Strasbourg, France). Slides were
promote the spread of neoplastic cells toward a more oxygen- analyzed with a Laser Radiance 2100 confocal microscope (Biorad, Hemel
Hempstead, UK) using fixed parameters in the laser settings.ated environment.
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Western blot analysis by the patient prior to surgery. SiHa human cervical carcinoma cells were
For Met expression analysis, cells were solubilized in boiling Laemmli buffer, inoculated subcutaneously (2  106 cells/animal) in 200 l of PBS into the
sonicated, and cleared by centrifugation. Total protein concentration was left posterior flank of three seven-week-old immunodeficient nu/nu female
determined using a BCA Protein Assay Reagent kit (Pierce Biotechnology, mice on Swiss CD-1 background (Charles River Laboratories, Calco, Italy).
Rockford, IL), and equal amounts (80 g) of proteins were resolved by SDS- After tumors had reached a size ranging between 0.6 and 1.0 cm in diameter,
PAGE on an 8% gel under reducing conditions. Separated proteins were mice were sacrificed and tumors were excised, embedded in Tissue-Tek
transferred onto a Hybond nitrocellulose membrane (Amersham Biosci- OCT compound (Sakura Finetek, Torrance, CA), and immediately frozen in
ences, Uppsala, Sweden) and analyzed by Western blotting using anti- liquid nitrogen. Human breast carcinoma samples were obtained from the
human Met (C-12; Santa Cruz) or anti-mouse Met (SP260; Santa Cruz) IRCC Pathology Division and immediately frozen after surgery as described
antibodies. After incubation with the appropriate secondary antibodies, nitro- above. For immunofluorescence analysis, 8 m thick frozen sections were
cellulose-bound antibodies were detected by short-wave chemilumines- fixed with 4% paraformaldehyde and blocked with 5% goat serum (Vector
cence using an ECL-plus kit (Amersham). Quantification of ECL signal was Laboratories, Burlingame, CA) in PBS containing 1% BSA and 0.3% Triton.
performed using a STORM apparatus and dedicated Image Quant software For HIF-1-Met localization studies, sections were double-stained with rab-
(Molecular Dynamics, Amersham Biosciences, Sunnyvale, CA). Anti-actin bit polyclonal anti-HIF-1 antibodies (H-206, Santa Cruz) and a mixture of
goat polyclonal antibodies used as control of protein loading were purchased two monoclonal anti-human Met antibodies (DO-24 and DN-30, Prat et al.,
from Santa Cruz (C-11). 1998). Goat anti-rabbit Alexa Fluor 488 and goat anti-mouse Alexa Fluor 546
(both from Molecular Probes) were used as secondary antibodies. Epitope
Gene probes and Northern blot analysis competition was performed by preincubating the anti-Met antibody mixture
Total RNA was isolated from hypoxic and normoxic cells with RNAwiz (Am- with a 5-fold molar excess of a purified human recombinant Met extracellular
bion, Austin, TX), resolved on a 0.8% agarose-formaldehyde gel (15 g each domain produced by baculovirus (a gift of Dr. S. Cavassa, University of
sample), and transferred to Hybond-N nylon membrane (Amersham). The Torino). For CD-31-Met localization studies, sections were double-stained
VEGF165 probe (Gene Bank # M32977) was obtained by RT-PCR using with rabbit polyclonal anti-human Met antibodies (C-12, Santa Cruz) and
HepG2-derived total RNA as template and the following oligonucleotides as either rat monoclonal anti-mouse CD-31 antibodies (MEC-13.3, Pharmingen,
primers: San Diego, CA) or mouse monoclonal anti-human CD-31 antibodies (JC70A,
5 GACGACGGATCCGGTCGGGCCTCCGAAACCATGAACTTTCTG 3 Dako A/S, Glostrup, Danmark). Goat anti-rabbit Alexa Fluor 488 and either
5 CGGCGGGTCGACCCGCCTCGGCTTGTCACATCTGCAAGTACG 3 goat anti-rat Alexa Fluor 546 or goat anti-mouse Alexa Fluor 546 (all from
The Met probe was obtained from the pCEV-Met plasmid (Michieli et Molecular Probes) were used as secondary antibodies. Epitope competition
al., 1999). Probes were labeled by random priming (Megaprime, Amersham) of the rabbit anti-human Met antibody was performed using the specific
using [-32P] dCTP. Hybridization was carried out at 42	C for 16 hr in the blocking peptide (sc-10 P, Santa Cruz) according to the manufacturer’s
presence of 50% formamide. Nylon membranes were washed twice at room instructions. Slides were mounted with Mowiol reagent (Hoechst) and ana-
temperature with 2 SSC-0.1% SDS and twice at 45	C with 0.1 SSC- lyzed by confocal microscopy using a Laser Radiance 2100 microscope
0.1% SDS, and autoradiographed. Image acquisition and analysis were (BioRad).
performed using a STORM apparatus and dedicated Image Quant software
(Molecular Dynamics). Ribosomal 28S RNA signal was used as loading Met activation and signal transduction analysis
control. For Met phosphorylation analysis, cells brought to 90% confluency in 2%
FBS were serum-starved for 24 hr and then subjected to normoxia or hypoxia
Promoter analysis for additional 48 hr in the same culturing conditions. Stimulation with HGF
The various met promoter constructs (P1-4) in the pGL-2 vector (Promega, (R&D, 30 ng/ml) was performed for 10 min at 37	C. Cells were lysed in RIPA
Madison, WI) have been described previously (Gambarotta et al., 1996). buffer (20 mM Tris-HCl [pH 7.4], 150 mM NaCl, 1% Triton X-100, 5 mM
Putative HBSs were mutated in their core region CGTG by a recombinant-
EDTA, 1% deoxycholate, 0.5% SDS) containing 1 mM Na3VO4 and a cocktailPCR based approach (as described in Michieli et al., 1999) as follows: HBS-4,
of protease inhibitors (pepstatin, leupeptin, aprotinin, soybean trypsin inhibi-
TCTC; HBS-5, TTTT. The AP-1 consensus sequence GCTGAGTCACT was
tor, PMSF). Cell extracts were sonicated and cleared by centrifugation. Total
mutated into TTATAGTCACT. Accuracy of the mutagenesis procedure was
protein concentration was determined using a BCA Protein Assay Reagent
verified by direct sequencing of mutant plasmids. Analysis of promoter activ-
kit (Pierce). Following dilution of SDS concentration to 0.1%, equal amounts
ity was performed in U2-OS or MLP-29 cells (106 cells/100 mm plate) trans-
of proteins were immunoprecipitated using either monoclonal anti-human
fected using Lipofectin reagent (Invitrogen, Carlsbad, CA) according to the
Met antibodies (DQ-13, Ruco et al., 1996) or polyclonal anti-mouse Met
manufacturer’s instructions. For hypoxia-induced transcription, cells were
antibodies (SP260, Santa Cruz). Immunoprecipitated proteins were resolvedtransfected with 10 g of the appropriate promoter construct and 0.1 g
by SDS-PAGE and analyzed by Western blotting as described above usingof a TK-Renilla reporter plasmid (Promega). Following transfection, cells were
anti-phosphotyrosine antibodies (UBI, Lake Placid, NY). The same blotsincubated for 24 hr in normoxic conditions and then exposed to normoxia or
were reprobed using anti-human Met (C-12, Santa Cruz) or anti-mouse Methypoxia for 48 hr. For HIF-1-induced transcription, cells were transfected with
(SP260, Santa Cruz) antibodies. For Gab-1 activation analysis, cells were3 g of the appropriate promoter construct, 7 g of a pCDNA-3 expression
subjected to the same treatments as above and then lysed in EB buffer (100vector (Invitrogen) containing either no insert or a human hif-1 cDNA (a gift
mM Tris-HCl [pH 7.4], 150 mM NaCl, 5 mM EDTA, 10% glycerol, 1% Tritonof Prof. J. Pouysse´gur, University of Nice, France), and 0.1 g of the TK-
X-100) containing 1 mM Na3VO4 and the above-described cocktail of prote-Renilla reporter plasmid. The inactive mutant form of hif-1 was generated
ase inhibitors. Cell extracts were cleared by centrifugation and total proteinas described (Richard et al., 2000). Following transfection, cells were incu-
concentration was determined as above. Equal amounts of proteins werebated for 72 hr in normoxic conditions. To measure luciferase activity, cells
immunoprecipitated using polyclonal anti-Gab-1 antibodies (UBI), resolvedwere processed using a Dual-Luciferase Reporter Assay System (Promega)
by SDS-PAGE and analyzed by Western blotting using anti-phosphotyrosineaccording to the manufacturer’s instructions, and 10 l of cell lysate was
antibodies. The same blots were reprobed with anti-Gab-1 antibodies orused to determine reporter enzyme activity using a Lumat LB 9507 lumino-
anti-Met antibodies. Quantification of ECL signal was performed as de-meter (Berthold, Bad Wilbad, Germany). Each experimental point was per-
scribed above.formed in triplicate and luciferase activity was normalized on Renilla activity
to standardize transfection efficiency.
Gene transfer and Met knockdown
U2-OS cells (106 cells/100 mm plate) were transfected using LipofectineTumor analysis
reagent as described above with 10 g of the pCEV expression vectorAll experiments with mice were performed according to international ethical
containing either no insert or the appropriate human met cDNA (wild-typeguidelines (EEC Council Directive 86/609; NIH Guide for the Care and Use
met and -met, Michieli et al., 1999; K1228A met, Crepaldi et al., 1994).of Laboratory Animals, NIH Publication # 85-23, 1985). Authorization was
Following selection with the appropriate selective agent, stable transfectantsgranted by the University of Torino Ethical Board and by the Italian Ministry
of Health. Human samples were obtained following written informed consent were pooled and analyzed for Met expression by Western blot of total cell
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Brizel, D.M., Scully, S.P., Harrelson, J.M., Layfield, L.J., Bean, J.M., Prosnitz,extracts. Inhibition of Met expression was achieved by RNA interference
L.R., and Dewhirst, M.W. (1996). Tumor oxygenation predicts for the likeli-using a 1:1 mixture of the following double-stranded oligoribonucleotides:
hood of distant metastases in human soft tissue sarcoma. Cancer Res. 56,MET1 5 ACUCUAGAUGCUCAGACUU 3
941–943.MET3 5 GUCAUAGGAAGAGGGCAUU 3
In order to verify the specificity of the knockdown effect, each oligoribo- Brizel, D.M., Sibley, G.S., Prosnitz, L.R., Scher, R.L., and Dewhirst, M.W.
nucleotide was point-mutated (*) to generate a pair of matched control oligos (1997). Tumor hypoxia adversely affects the prognosis of carcinoma of the
(mutated bases are underlined): head and neck. Int. J. Radiat. Oncol. Biol. Phys. 38, 285–289.
MET1* 5 AGUCUACAUGCUCACACUU 3
Cairns, R.A., Kalliomaki, T., and Hill, R.P. (2001). Acute (cyclic) hypoxiaMET3* 5 CUCAUAGGAAGACCCCAUU 3
enhances spontaneous metastasis of KHT murine tumors. Cancer Res. 61,Oligoribonucleotides were produced using the Silencer siRNA Construc-
8903–8908.
tion Kit (Ambion, Austin, TX) according to the manufacturer’s instructions.
Transfections (200 nM total oligoribonucleotide mixture) were performed Chambers, A.F., Groom, A.C., and MacDonald, I.C. (2002). Dissemination
and growth of cancer cells in metastatic sites. Nature Rev. Cancer 2, 563–using Oligofectamine reagent (Invitrogen) according to manufacturer’s in-
572.structions. Cells were incubated for 72 hr prior to Met levels determination
or biological testing. Comoglio, P.M., and Trusolino, L. (2002). Invasive growth: from development
to metastasis. J. Clin. Invest. 109, 857–862.
Acknowledgments
Crepaldi, T., Prat, M., Giordano, S., Medico, E., and Comoglio, P.M. (1994).
Generation of a truncated hepatocyte growth factor receptor in the endoplas-We are grateful to Piero Sismondi, Nicoletta Biglia, and Alberto Pisacane
mic reticulum. J. Biol. Chem. 269, 1750–1755.for human breast carcinoma samples, Giovanna Gambarotta for the met
promoter constructs, Jacques Pouysse´gur for HIF-1 cDNA, Livio Trusolino, Damert, A., Ikeda, E., and Risau, W. (1997). Activator-protein-1 binding
Michele De Palma, and Mary Venneri for helpful discussion, and to Paolo potentiates the hypoxia-inducible factor-1-mediated hypoxia-induced tran-
Ferrero, Ada Arnesano, Raffaella Albano, Laura Palmas, Solange Tienga, scriptional activation of vascular-endothelial growth factor expression in C6
and Francesca Grasso for skilled technical assistance. This work has been glioma cells. Biochem. J. 327, 419–423.
supported in part by the Giovanni Armenise-Harvard Foundation, the Italian
Date, K., Matsumoto, K., Kuba, K., Shimura, H., Tanaka, M., and Nakamura,Association for Cancer Research (AIRC), and the Compagnia S. Paolo di
T. (1998). Inhibition of tumor growth and invasion by a four-kringle antagonist
Torino Foundation. (HGF/NK4) for hepatocyte growth factor. Oncogene 17, 3045–3054.
Di Renzo, M.F., Olivero, M., Ferro, S., Prat, M., Bongarzone, I., Pilotti, S.,
Belfiore, A., Costantino, A., Vigneri, R., Pierotti, M.A., and Comoglio, P.M.
(1992). Overexpression of the c-MET/HGF receptor gene in human thyroidReceived: November 18, 2002
carcinomas. Oncogene 7, 2549–2553.Revised: March 24, 2003
Published: April 21, 2003 Di Renzo, M.F., Olivero, M., Giacomini, A., Porte, H., Chastre, E., Mirossay,
L., Nordlinger, B., Bretti, S., Bottardi, S., Giordano, S., et al. (1995). Overex-
pression and amplification of the met/HGF receptor gene during the progres-References
sion of colorectal cancer. Clin. Cancer Res. 1, 147–154.
Aguirre Ghiso, J.A., Alonso, D.F., Farias, E.F., Gomez, D.E., and de Kier Joffe, Di Renzo, M.F., Olivero, M., Martone, T., Maffe, A., Maggiora, P., Stefani,
E.B. (1999). Deregulation of the signaling pathways controlling urokinase A.D., Valente, G., Giordano, S., Cortesina, G., and Comoglio, P.M. (2000).
production. Its relationship with the invasive phenotype. Eur. J. Biochem. Somatic mutations of the MET oncogene are selected during metastatic
263, 295–304. spread of human HNSC carcinomas. Oncogene 19, 1547–1555.
Andermarcher, E., Surani, M., and Gherardi, E. (1996). Co-expression of the Folkman, J. (1999). Angiogenesis research: from laboratory to clinic. Forum
HGF/SF and c-met genes during early mouse embryogenesis precedes (Genova) 9 (Suppl. 3), 59–62.
reciprocal expression in adjacent tissues during organogenesis. Dev. Genet.
Follenzi, A., Bakovic, S., Gual, P., Stella, M.C., Longati, P., and Comoglio,18, 254–266.
P.M. (2000). Cross-talk between the proto-oncogenes Met and Ron. Onco-
gene 19, 3041–3049.Bardelli, A., Longati, P., Williams, T.A., Benvenuti, S., and Comoglio, P.M.
(1999). A peptide representing the carboxyl-terminal tail of the met receptor
Forsythe, J.A., Jiang, B.H., Iyer, N.V., Agani, F., Leung, S.W., Koos, R.D.,inhibits kinase activity and invasive growth. J. Biol. Chem. 274, 29274–29281.
and Semenza, G.L. (1996). Activation of vascular endothelial growth factor
gene transcription by hypoxia-inducible factor 1. Mol. Cell. Biol. 16, 4604–Birchmeier, W., Brinkmann, V., Niemann, C., Meiners, S., DiCesare, S., Naun-
4613.dorf, H., and Sachs, M. (1997). Role of HGF/SF and c-Met in morphogenesis
and metastasis of epithelial cells. Ciba Found. Symp. 212, 230–240. Frisch, S.M., and Francis, H. (1994). Disruption of epithelial cell-matrix inter-
actions induces apoptosis. J. Cell Biol. 124, 619–626.Blagosklonny, M.V. (2001). Hypoxia-inducible factor: Achilles’ heel of antian-
giogenic cancer therapy. Int. J. Oncol. 19, 257–262. Frisch, S.M., and Screaton, R.A. (2001). Anoikis mechanisms. Curr. Opin.
Cell Biol. 13, 555–562.Boccaccio, C., Gaudino, G., Gambarotta, G., Galimi, F., and Comoglio, P.M.
(1994). Hepatocyte growth factor (HGF) receptor expression is inducible and Gambarotta, G., Pistoi, S., Giordano, S., Comoglio, P.M., and Santoro, C.
is part of the delayed-early response to HGF. J. Biol. Chem. 269, 12846– (1994). Structure and inducible regulation of the human MET promoter. J.
12851. Biol. Chem. 269, 12852–12857.
Boccaccio, C., Ando`, M., Tamagnone, L., Bardelli, A., Michieli, P., Battistini, Gambarotta, G., Boccaccio, C., Giordano, S., Ando`, M., Stella, M.C., and
C., and Comoglio, P.M. (1998). Induction of epithelial tubules by growth Comoglio, P.M. (1996). Ets up-regulates MET transcription. Oncogene 13,
factor HGF depends on the STAT pathway. Nature 391, 285–288. 1911–1917.
Boix, L., Rosa, J.L., Ventura, F., Castells, A., Bruix, J., Rodes, J., and Bar- Gerber, H.-P., Condorelli, F., Park, J., and Ferrara, N. (1997). Differential
trons, R. (1994). c-met mRNA overexpression in human hepatocellular carci- transcriptional regulation of the two vascular endothelial growth factor recep-
noma. Hepatology 19, 88–91. tor genes. J. Biol. Chem. 272, 23659–23667.
Brinkmann, V., Foroutan, H., Sachs, M., Weidner, K.M., and Birchmeier, W. Gherardi, E., Gray, J., Stoker, M., Perryman, M., and Furlong, R. (1989).
(1995). Hepatocyte growth factor/scatter factor induces a variety of tissue- Purification of scatter factor, a fibroblast-derived basic protein that modu-
specific morphogenic programs in epithelial cells. J. Cell Biol. 131, 1573– lates epithelial interactions and movement. Proc. Natl. Acad. Sci. USA 86,
5844–5848.1586.
CANCER CELL : APRIL 2003 359
A R T I C L E
Giordano, S., Corso, S., Conrotto, P., Artigiani, S., Gilestro, G., Barberis, D., Michieli, P., Basilico, C., Pennacchietti, S., Maffe, A., Tamagnone, L., Gior-
Tamagnone, L., and Comoglio, P.M. (2002). The semaphorin 4D receptor dano, S., Bardelli, A., and Comoglio, P.M. (1999). Mutant Met-mediated
controls invasive growth by coupling with Met. Nat. Cell Biol. 4, 720–724. transformation is ligand-dependent and can be inhibited by HGF antagonists.
Oncogene 18, 5221–5231.
Graeber, T.G., Osmanian, C., Jacks, T., Housman, D.E., Koch, C.J., Lowe,
S.W., and Giaccia, A.J. (1996). Hypoxia-mediated selection of cells with Michiels, C., Minet, E., Michel, G., Mottet, D., Piret, J.P., and Raes, M. (2001).
diminished apoptotic potential in solid tumours. Nature 379, 88–91. HIF-1 and AP-1 cooperate to increase gene expression in hypoxia: role of
MAP kinases. IUBMB Life 52, 49–53.
Hanahan, D., and Weinberg, R.A. (2000). The hallmarks of cancer. Cell 100,
57–70. Miyazawa, K., Shimomura, T., Naka, D., and Kitamura, N. (1994). Proteolytic
activation of hepatocyte growth factor in response to tissue injury. J. Biol.
Hannon, G.J. (2002). RNA interference. Nature 418, 244–251. Chem. 269, 8966–8970.
Harris, A.L. (2002). Hypoxia-a key regulatory factor in tumor growth. Nature Montesano, R., Matsumoto, K., Nakamura, T., and Orci, L. (1991). Identifica-
Rev. Cancer 2, 38–47.
tion of a fibroblast-derived epithelial morphogen as hepatocyte growth fac-
tor. Cell 67, 901–908.Ho¨ckel, M., and Vaupel, P. (2001). Tumor hypoxia: definitions and current
clinical, biologic, and molecular aspects. J. Natl. Cancer Inst. 93, 266–276.
Morotti, A., Mila, S., Accornero, P., Tagliabue, E., and Ponzetto, C. (2002).
K252a inhibits the oncogenic properties of Met, the HGF receptor. OncogeneHo¨ckel, M., Schlenger, K., Aral, B., Mitze, M., Schaffer, U., and Vaupel, P.
21, 4885–4893.(1996). Association between tumor hypoxia and malignant progression in
advanced cancer of the uterine cervix. Cancer Res. 56, 4509–4515.
Nakamura, T., Teramoto, H., and Ichihara, A. (1986). Purification and charac-
terization of a growth factor from rat platelets for mature parenchymal hepa-Ho¨ckel, M., Schlenger, K., Ho¨ckel, S., and Vaupel, P. (1999). Hypoxic cervical
tocytes in primary cultures. Proc. Natl. Acad. Sci. USA 83, 6489–6493.cancers with low apoptotic index are highly aggressive. Cancer Res. 59,
4525–4528.
Nakamura, T., Nishizawa, T., Hagiya, M., Seki, T., Shimonishi, M., Sugimura,
A., Tashiro, K., and Shimizu, S. (1989). Molecular cloning and expression ofKimura, H., Weisz, A., Kurashima, Y., Hashimoto, K., Ogura, T., D’Acquisto,
human hepatocyte growth factor. Nature 342, 440–443.F., Addeo, R., Makuuchi, M., and Esumi, H. (2000). Hypoxia response ele-
ment of the human vascular endothelial growth factor gene mediates tran-
Naldini, L., Vigna, E., Ferracini, R., Longati, P., Gandino, L., Prat, M., andscriptional regulation by nitric oxide: control of hypoxia-inducible factor-1
Comoglio, P.M. (1991). The tyrosine kinase encoded by the MET proto-activity by nitric oxide. Blood 95, 189–197.
oncogene is activated by autophosphorylation. Mol. Cell. Biol. 11, 1793–
1803.Koochekpour, S., Jeffers, M., Wang, P.H., Gong, C., Taylor, G.A., Roessler,
L.M., Stearman, R., Vasselli, J.R., Stetler-Stevenson, W.G., Kaelin, W.G.,
Naldini, L., Tamagnone, L., Vigna, E., Sachs, M., Hartmann, G., Birchmeier,Jr., et al. (1999). The von Hippel-Lindau tumor suppressor gene inhibits
W., Daikuhara, Y., Tsubouchi, H., Blasi, F., and Comoglio, P.M. (1992).hepatocyte growth factor/scatter factor-induced invasion and branching
Extracellular proteolytic cleavage by urokinase is required for activation ofmorphogenesis in renal carcinoma cells. Mol. Cell. Biol. 19, 5902–5912.
hepatocyte growth factor/scatter factor. EMBO J. 11, 4825–4833.
Levy, A.P., Levy, N.S., Wegner, S., and Goldberg, M.A. (1995). Transcrip-
Norris, M.L., and Millhorn, D.E. (1995). Hypoxia-induced protein binding totional regulation of the rat vascular endothelial growth factor gene by hypoxia.
O2-responsive sequences on the tyrosine hydroxylase gene. J. Biol. Chem.J. Biol. Chem. 270, 13333–13340.
270, 23774–23779.
Liotta, L.A., and Kohn, E.C. (2001). The microenvironment of the tumour-
O’Reilly, M.S., Holmgren, L., Shing, Y., Chen, C., Rosenthal, R.A., Moses,host interface. Nature 411, 375–379.
M., Lane, W.S., Cao, Y., Sage, E.H., and Folkman, J. (1994). Angiostatin: a
Liu, C., Park, M., and Tsao, M.S. (1992). Overexpression of c-met proto- novel angiogenesis inhibitor that mediates the suppression of metastases
oncogene but not epidermal growth factor receptor or c-erbB-2 in primary by a Lewis lung carcinoma. Cell 79, 315–328.
human colorectal carcinomas. Oncogene 7, 181–185.
Oh, R.R., Park, J.Y., Lee, J.H., Shin, M.S., Kim, H.S., Lee, S.K., Kim, Y.S.,
Lyon, M., Deakin, J.A., Mizuno, K., Nakamura, T., and Gallagher, J.T. (1994). Lee, S.H., Lee, S.N., Yang, Y.M., et al. (2002). Expression of HGF/SF and
Interaction of hepatocyte growth factor with heparan-sulfate. Elucidation Met protein is associated with genetic alterations of VHL gene in primary
of the major heparan sulfate structural determinants. J. Biol. Chem. 269, renal cell carcinomas. APMIS 110, 229–238.
11216–11223.
Orian-Rousseau, V., Chen, L., Sleeman, J.P., Herrlich, P., and Ponta, H.
Maity, A., and Solomon, D. (2000). Both increased stability and transcription (2002). CD44 is required for two consecutive steps in HGF/c-Met signaling.
contribute to the induction of the urokinase plasminogen activator receptor Genes Dev. 16, 3074–3086.
(uPAR) message by hypoxia. Exp. Cell Res. 255, 250–257.
Park, W.S., Dong, S.M., Kim, S.Y., Na, E.Y., Shin, M.S., Pi, J.H., Kim, B.J.,
Maranchie, J.K., Vasselli, J.R., Riss, J., Bonifacino, J.S., Linehan, W.M., and Bae, J.H., Hong, Y.K., Lee, K.S., et al. (1999). Somatic mutations in the kinase
Klausner, R.D. (2002). The contribution of VHL substrate binding and HIF1- domain of the Met/hepatocyte growth factor receptor gene in childhood
to the phenotype of VHL loss in renal carcinoma. Cancer Cell 1, 247–255. hepatocellular carcinomas. Cancer Res. 59, 307–310.
Matsumoto, K., and Nakamura, T. (1997). HGF: its organotrophic role and Postovit, L.M., Adams, M.A., Lash, G.E., Heaton, J.P., and Graham, C.H.
therapeutic potential. Ciba Found. Symp. 212, 198–211. (2002). Oxygen-mediated regulation of tumor cell invasiveness. Involvement
of a nitric oxide signaling pathway. J. Biol. Chem. 277, 35730–35737.Maxwell, P.H., Wiesener, M.S., Chang, G.W., Clifford, S.C., Vaux, E.C.,
Cockman, M.E., Wykoff, C.C., Pugh, C.W., Maher, E.R., and Ratcliffe, P.J. Prat, M., Crepaldi, T., Pennacchietti, S., Bussolino, F., and Comoglio, P.M.
(1999). The tumour suppressor protein VHL targets hypoxia-inducible factors (1998). Agonistic monoclonal antibodies against the Met receptor dissect
for oxygen-dependent proteolysis. Nature 399, 271–275. the biological responses to HGF. J. Cell Sci. 111, 237–247.
Medico, E., Mongiovi, A.M., Huff, J., Jelinek, M.A., Follenzi, A., Gaudino, G., Richard, D.E., Berra, E., and Pouysse´gur, J. (2000). Nonhypoxic pathway
Parsons, J.T., and Comoglio, P.M. (1996). The tyrosine kinase receptors mediates the induction of Hypoxia-Inducible Factor 1 in vascular smooth
Ron and Sea control “scattering” and morphogenesis of liver progenitor muscle cells. J. Biol. Chem. 275, 26765–26771.
cells in vitro. Mol. Biol. Cell 7, 495–504.
Rofstad, E.K., Rasmussen, H., Galappathi, K., Mathiesen, B., Nilsen, K.,
Meyer, M., Clauss, M., Lepple-Wienhues, A., Waltenberger, J., Augustin, and Graff, B.A. (2002). Hypoxia promotes lymph node metastasis in human
H.G., Ziche, M., Lanz, C., Buttner, M., Rziha, H.J., and Dehio, C. (1999). A melanoma xenografts by up-regulating the urokinase-type plasminogen acti-
novel vascular endothelial growth factor encoded by Orf virus, VEGF-E, vator receptor. Cancer Res. 62, 1847–1853.
mediates angiogenesis via signalling through VEGFR-2 (KDR) but not
VEGFR-1 (Flt-1) receptor tyrosine kinases. EMBO J. 18, 363–374. Rubin, J.S., Bottaro, D.P., and Aaronson, S.A. (1993). Hepatocyte growth
360 CANCER CELL : APRIL 2003
A R T I C L E
factor/scatter factor and its receptor, the c-met proto-oncogene product. N. (1995). Placental defect and embryonic lethality in mice lacking hepatocyte
growth factor/scatter factor. Nature 373, 702–705.Biochim. Biophys. Acta 1155, 357–371.
Vande Woude, G.F., Jeffers, M., Cortner, J., Alvord, G., Tsarfaty, I., andRuco, L.P., Ranalli, T., Marzullo, A., Bianco, P., Prat, M., Comoglio, P.M.,
Resau, J. (1997). Met-HGF/SF: tumorigenesis, invasion and metastasis. Cibaand Baroni, C.D. (1996). Expression of Met protein in thyroid tumours. J.
Found. Symp. 212, 119–130.Pathol. 180, 266–270.
Vaupel, P., Kallinowski, F., and Okunieff, P. (1989). Blood flow, oxygen andSa´nchez-Elsner, T., Botella, L.M., Velasco, B., Langa, C., and Bernabeu,
nutrient supply, and metabolic microenvironment of human tumors: a review.C. (2002). Endoglin expression is regulated by transcriptional cooperation
Cancer Res. 49, 6449–6465.between the hypoxia and transforming growth factor-beta pathways. J. Biol.
Chem. 277, 43799–43808. Vukovic, V., Haugland, H.K., Nicklee, T., Morrison, A.J., and Hedley, D.W.
(2001). Hypoxia-inducible factor-1alpha is an intrinsic marker for hypoxia in
Schmidt, C., Bladt, F., Goedecke, S., Brinkmann, V., Zschiesche, W., Sharpe, cervical cancer xenografts. Cancer Res. 61, 7394–7398.
M., Gherardi, E., and Birchmeier, C. (1995). Scatter factor/hepatocyte growth
Weidner, K.M., Di Cesare, S., Sachs, M., Brinkmann, V., Behrens, J., andfactor is essential for liver development. Nature 373, 699–702.
Birchmeier, W. (1996). Interaction between Gab1 and the c-Met receptor
Schmidt, L., Junker, K., Nakaigawa, N., Kinjerski, T., Weirich, G., Miller, M., tyrosine kinase is responsible for epithelial morphogenesis. Nature 384,
Lubensky, I., Neumann, H.P., Brauch, H., Decker, J., et al. (1999). Novel 173–176.
mutations of the MET proto-oncogene in papillary renal carcinomas. Onco-
Woodhouse, E.C., Chuaqui, R.F., and Liotta, L.A. (1997). General mecha-gene 18, 2343–2350.
nisms of metastasis. Cancer 80, 1529–1537.
Semenza, G.L. (2001). HIF-1, O2, and the 3 PHDs: how animal cells signal Woolf, A.S., Kolatsi-Joannou, M., Hardman, P., Andermarcher, E., Moorby,hypoxia to the nucleus. Cell 107, 1–3.
C., Fine, L.G., Jat, P.S., Noble, M.D., and Gherardi, E. (1995). Roles of
hepatocyte growth factor/scatter factor and the met receptor in the earlySeol, D.W., Chen, Q., and Zarnegar, R. (2000). Transcriptional activation of
development of the metanephros. J. Cell Biol. 128, 171–184.the hepatocyte growth factor receptor (c-met) gene by its ligand (hepatocyte
growth factor) is mediated through AP-1. Oncogene 19, 1132–1137. Xu, Q., Ji, Y.S., and Schmedtje, J.F., Jr. (2000). Sp1 increases expression
of cyclooxygenase-2 in hypoxic vascular endothelium. J. Biol. Chem. 275,Shweiki, D., Itin, A., Soffer, D., and Keshet, E. (1992). Vascular endothelial
24583–24589.growth factor induced by hypoxia may mediate hypoxia-initiated angiogen-
esis. Nature 359, 843–845. Yamashita, K., Discher, D.J., Hu, J., Bishopric, N.H., and Webster, K.A.
(2001). Molecular regulation of the endothelin-1 gene by hypoxia. J. Biol.
Stoker, M., and Gherardi, E. (1991). Regulation of cell movement: the moto- Chem. 276, 12645–12653.
genic cytokines. Biochim. Biophys. Acta 1072, 81–102.
Yanagita, K., Matsumoto, K., Sekiguchi, K., Ishibashi, H., Niho, Y., and
Stoker, N., Gherardi, E., Perryman, M., and Grey, J. (1987). Scatter factor is Nakamura, T. (1993). Hepatocyte growth factor may act as a pulmotrophic
a fibroblast-derived modulator of epithelial cell motility. Nature 327, 239–242. factor on lung regeneration after acute lung injury. J. Biol. Chem. 268, 21212–
21217.
Sundfor, K., Lyng, H., and Rofstad, E.K. (1998). Tumour hypoxia and vascular
Yang, Y., Spitzer, E., Meyer, D., Sachs, M., Niemann, C., Hartmann, G.,density as predictors of metastasis in squamous cell carcinoma of the uterine
Weidner, K.M., Birchmeier, C., and Birchmeier, W. (1995). Sequential require-cervix. Br. J. Cancer 78, 822–827.
ment of hepatocyte growth factor and neuregulin in the morphogenesis and
Tacchini, L., Dansi, P., Matteucci, E., and Desiderio, M.A. (2001). Hepatocyte differentiation of the mammary gland. J. Cell Biol. 131, 215–226.
growth factor signalling stimulates hypoxia inducible factor-1 (HIF-1) activity
Young, S.D., and Hill, R.P. (1990). Effects of reoxygenation of cells fromin HepG2 hepatoma cells. Carcinogenesis 22, 1363–1371.
hypoxic regions of solid tumors: anticancer drug sensitivity and metastatic
potential. J. Natl. Cancer Inst. 82, 338–339.Takayama, H., La Rochelle, W.J., Anver, M., Bockman, D.E., and Merlino,
G. (1996). Scatter factor/hepatocyte growth factor as a regulator of skeletal Young, S.D., Marshall, R.S., and Hill, R.P. (1988). Hypoxia induces DNA
muscle and neural crest development. Proc. Natl. Acad. Sci. USA 93, 5866– overreplication and enhances metastatic potential of murine tumor cells.
5871. Proc. Natl. Acad. Sci. USA 85, 9533–9537.
Trusolino, L., and Comoglio, P.M. (2002). Scatter-factor and semaphorin Yu, J.L., Rak, J.W., Coomber, B.L., Hicklin, D.J., and Kerbel, R.S. (2002).
receptors: cell signalling for invasive growth. Nature Rev. Cancer 4, 289–300. Effect of p53 status on tumor response to antiangiogenic therapy. Science
295, 1526–1528.
Trusolino, L., Bertotti, A., and Comoglio, P.M. (2001). A signaling adapter
Yuan, Y., Hilliard, G., Ferguson, T., and Millhorn, D.E. (2003). Cobalt inhibitsfunction for alpha6beta4 integrin in the control of HGF-dependent invasive
the interaction between hypoxia inducible factor-alpha and von Hippel-Lin-growth. Cell 107, 643–654.
dau protein by direct binding to hypoxia inducible factor-alpha. J. Biol.
Chem., in press.Uehara, Y., Minowa, O., Mori, C., Shiota, K., Kuno, J., Noda, T., and Kitamura,
CANCER CELL : APRIL 2003 361
